KalVista Pharmaceuticals (NasdaqGM:KALV) Earnings Call Presentation

Market Opportunity and Clinical Performance - EKTERLY is the first and only oral on-demand therapy for HAE, addressing a market where 1/3 to 1/2 of attacks currently go untreated[20] - Clinical data from 2,753 treated attacks demonstrates a median time to treatment of 10 minutes and a median time to symptom relief of 1.3 hours[27] - The company aims to expand the current $650 million U.S. market to a $1.5 billion total addressable market by increasing treatment rates and converting patients from injectable generics[40][41] Commercial Execution and Growth - Since the U.S. launch, the company achieved approximately $49 million in net sales, with 1,318 patient start forms and 580 unique prescribers as of December 31, 2025[38] - Q4 2025 revenue was driven by strong adoption, with refills accounting for over 50% of quarterly revenue and 85% of Tier 1 accounts prescribing the therapy[38] - The company has secured regulatory approvals in 7 key global markets, including the US, EU, UK, Switzerland, Australia, Japan, and Singapore[11][44] Strategic Pipeline and Future Outlook - The company plans to file an NDA in Q3 2026 for a pediatric indication (ages 2-11) to provide a complete family solution, with an anticipated launch in 2027[30][43] - Future growth strategy focuses on leveraging internal oral Factor XIIa inhibitor programs and acquiring external assets to address rare diseases with high unmet needs[47][49] - The company has established a strong financial foundation with intellectual property protection extending into the 2040s[49]